HOOKIPA Pharma's HB-700 Shows Strong Preclinical Progress

HOOKIPA Pharma Inc. is a next-generation clinical-stage  Biopharmaceutical company developing immunotherapeutics for the treatment of cancer and complex infectious diseases. The company today announced the presentation of preclinical data related to the HB-700 program. It is a program for treatment of Kirsten Rat Sarcoma (KRAS). The dataset will be presented at the 6th Annual RAS-Targeted Drug Development Summit, which will be held in Boston, Massachusetts from September 24 to September 26, 2024.

Mark Winderlich, PhD, Chief Research & Development Officer, said in a statement, “HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700 for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found in pancreatic, colorectal and lung cancers. While a number of KRAS programs are focused on a single mutation, our program is uniquely suited to target the most prevalent KRAS mutations of these cancers in a single therapy.”

He further added, “HOOKIPA’s approach could enable HB-700 to be a widely used, multi-KRAS therapy. The preclinical dataset has demonstrated safety, induction of target-specific CD8+ T-cells, and target cell killing in several different animal and translational models. With IND clearance, received from the FDA in Q2 2024, HB-700 is a Phase 1 ready asset.”

The oral presentation titled "Development of an Arenavirus-Based Immunotherapy for Treating KRAS Mutant Cancer" will be held virtually during the session on Drug Discovery & Preclinical Development. It is officially scheduled for Wednesday, September 25, from 12:45 to 1:15 PM ET.